Literature DB >> 27636560

PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics.

Alison E Fohner1, Ellen M McDonagh, John P Clancy, Michelle Whirl Carrillo, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27636560      PMCID： PMC5140711          DOI： 10.1097/FPC.0000000000000246

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  25 in total

1.  Pharmaceutical Approval Update.

Authors:  Kunj Gohil
Journal:  P T       Date:  2015-09

Review 2.  ACOG Committee Opinion No. 486: Update on carrier screening for cystic fibrosis.

Authors: 
Journal:  Obstet Gynecol       Date:  2011-04       Impact factor: 7.661

Review 3.  Ivacaftor for patients with cystic fibrosis.

Authors:  Claire E Wainwright
Journal:  Expert Rev Respir Med       Date:  2014-08-22       Impact factor: 3.772

4.  Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels.

Authors:  Z Kopeikin; Z Yuksek; H-Y Yang; S G Bompadre
Journal:  J Cyst Fibros       Date:  2014-05-03       Impact factor: 5.482

5.  Sweat chloride is not a useful marker of clinical response to Ivacaftor.

Authors:  Peter J Barry; Andrew M Jones; Anthony K Webb; Alexander R Horsley
Journal:  Thorax       Date:  2013-11-20       Impact factor: 9.139

Review 6.  A safety evaluation of ivacaftor for the treatment of cystic fibrosis.

Authors:  Susanna A McColley
Journal:  Expert Opin Drug Saf       Date:  2016-04-07       Impact factor: 4.250

Review 7.  Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.

Authors:  Nico Derichs
Journal:  Eur Respir Rev       Date:  2013-03-01

8.  Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.

Authors:  Jane Davies; Helen Sheridan; Nicholas Bell; Steve Cunningham; Stephanie D Davis; J Stuart Elborn; Carlos E Milla; Timothy D Starner; Daniel J Weiner; Po-Shun Lee; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2013-09-10       Impact factor: 30.700

9.  Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein.

Authors:  Sarah M Robertson; Xia Luo; Neeraj Dubey; Chonghua Li; Ajit B Chavan; Geoffrey S Gilmartin; Mark Higgins; Lisa Mahnke
Journal:  J Clin Pharmacol       Date:  2014-08-27       Impact factor: 3.126

10.  Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.

Authors:  John J Brewington; Gary L McPhail; John P Clancy
Journal:  Expert Rev Respir Med       Date:  2015-12-09       Impact factor: 3.772
View more
  3 in total

Review 1.  Ligand binding at the protein-lipid interface: strategic considerations for drug design.

Authors:  Jian Payandeh; Matthew Volgraf
Journal:  Nat Rev Drug Discov       Date:  2021-07-13       Impact factor: 84.694

Review 2.  The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis.

Authors:  Caitlyn Harvey; Sinead Weldon; Stuart Elborn; Damian G Downey; Clifford Taggart
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

Review 3.  Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?

Authors:  Eva Choong; Alain Sauty; Angela Koutsokera; Sylvain Blanchon; Pascal André; Laurent Decosterd
Journal:  Pharmaceutics       Date:  2022-08-11       Impact factor: 6.525
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.